US approves Lembaz to reduce deaths in early-onset Niemann-Pick type C


The injection is the first treatment shown to reduce the risk of death in infantile-onset Niemann-Pick disease type C. Adults and children weighing at least 7 kg qualify if their neurological symptoms began before age 6.
Sole source: The US Food and Drug Administration approved Lembaz (adrabetadex) on 17 November 2026, making it the first treatment shown to reduce the risk of death in people with infantile-onset Niemann-Pick disease type C, or NPC. Approval covers adults as well as children, provided they meet the weight and symptom-onset requirements.
Two treatments were already approved for NPC, but neither had been shown to reduce the risk of death, the FDA said. Both have age and weight restrictions that limit access for the youngest and most seriously affected patients.
The FDA says NPC is a rare inherited lysosomal storage disorder in which cells cannot properly process cholesterol and other fats. These substances build up, particularly in the brain, causing progressive loss of movement, coordination and the ability to swallow. The FDA describes the form in which neurological symptoms begin before age 6 as the most serious.
The FDA evaluated 36 patients treated with Lembaz across three clinical studies and an expanded-access program, which provided the drug outside those studies. All had neurological symptoms that began before age 6. The agency compared their survival with a matched external control group.
The FDA found a 55% lower risk of death in the treated group than in the control group. Median survival was 8.5 years for treated patients and 4.9 years for controls. The agency said the survival benefit was observed whether or not patients also took miglustat, a drug used off-label for NPC.
The FDA says a trained health care provider injects Lembaz directly into the spinal canal every two weeks. The drug carries a boxed warning for hearing impairment, including permanent hearing loss. Patients should have a comprehensive hearing evaluation before treatment and regular checks afterward; the dose may need to be adjusted based on the results.
Other common side effects listed by the FDA include balance and coordination problems, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea and cough.
The FDA granted approval to Mandos, a subsidiary of biotechnology company Beren Therapeutics.
President Bola Tinubu sent the amendment to the Senate on 17 November 2026. Senate President Godswill Akpabio referred his letter to a committee, which he directed to report back as soon as practicable.
3 min

Niue Ocean Wide Trust, Mahindra Last Mile Mobility and Ørsted also won at the November 17 ceremony in Mumbai. Each winner will receive £1 million to expand its work.
3 min

The researchers attribute 21–31 million metric tons of carbon dioxide to electricity used by 403 hyperscale facilities between May 2024 and April 2025, using regional power mixes and assumptions about operating loads.
3 min